Results 171 to 180 of about 364,712 (294)

Meta-Analysis of the Placebo Response in Chronic and Episodic Migraine: Insights from Migraine Preventive Drug Trials. [PDF]

AAPS J
Nookala AR, Panse N, Gottipati G, Fitter HD, Uppoor R, Mehta M, Sabarinath S.   +6 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis. [PDF]

Arthritis Rheumatol
Kerschbaumer A, Steiner M, Khalili S, Shehab A, Jordanov A, Wildner B, Maad M, Smolen JS, Aletaha D.   +8 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

The Functional Anatomy of Nociception: Effective Connectivity in Chronic Pain and Placebo Response. [PDF]

J Neurosci
Nara S, Baliki MN, Friston KJ, Ray D.
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

The Role of Oxytocin and Sex in Analgesic Placebo-Response: Exploratory Analysis from a Sham Randomized Clinical Trial in Chronic Back-Pain Patients. [PDF]

J Clin Med
Mendelson-Keypur R, Shani A, Granot M, Agostinho MR, Paltzur E, Treister R, Rahamimov N.   +6 more
europepmc   +1 more source

Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review. [PDF]

Int J Neuropsychopharmacol, 2022
Huneke NTM, Aslan IH, Fagan H, Phillips N, Tanna R, Cortese S, Garner M, Baldwin DS.   +7 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Predictors of Placebo Response in the Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors. [PDF]

J Child Adolesc Psychopharmacol
Verdes A, Bhattachan S, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, Spanos M, Chandrasekhar T, Rockhill C, Palumbo M, Minjarez M, Nowinski L, Marler S, Siecinski S, Giamberardino S, Gregory SG, Veenstra-VanderWeele J, Sikich L, Jutla A.   +19 more
europepmc   +1 more source